玻璃体腔注射贝伐单抗治疗慢性 CSC 的长期疗效观察 Long-term effect of intravitreal bevacizumab injection for chronic central serous chorioretinopathy

Xi Chen, Qing-Huai Liu, Xiao-Yi Liu
unpublished
誗AIM: To evaluate the safety and long-term efficacy of intravitreal bevacizumab injection (IVB) as therapy for chronic central serous chorioretinopathy (CSC). 誗METHODS: Six patients (6 eyes) with CSC were treated with an intravitreal injection of bevacizumab (1. 25mg / 0郾 05mL). 5 patients received second intravitreal injection of bevacizumab 3 months after the first injection. Patients had follow-up on 1, 3, 6, 12, 24 months after the injections. Outcome measures included pre and
more » ... e and post-treatment changes in best-corrected visual acuity, intraocular pressure (IOP) , subretinal fluid (SRF) measurement with optical coherence tomography (OCT) , changes in fluorescein angiography (FA). 誗 RESULTS: After the first injection, 1 patient showed resolution of SRF completely, while his visual acuity showed no change; 1 patient whose visual acuity improved and SRF resolved completely on 1 month recurred; 3 patients showed no obvious changes in the SRF and in visual acuity; 1 patient showed decreased thickness of SRF while his visual acuity were stable. After the second injection, 1 patient showed resolution of SRF completely with improved his visual acuity; 2 patients showed resolution of SRF completely, while his visual acuity showed no change; the others showed no obvious change. The changes of SRF and visual acuity seemed to have no direct relation. The visual acuity showed no significant difference before and 12, 24 months after the first injections. Pre and post-treatment the IOP of the 6 patients all belong to normal range. No cases of endophthalmitis were reported. 誗 CONCLUSION: IVB have some effect in chronic CSC cases in improving subretinal fluid resolution. But IVB have no long-term effect on improving visual acuity. 誗 KEYWORDS: chronic central serous chorioretinopathy; bevacizumab; anti-VEGF therapy Citation:Chen X, Liu QH, Liu XY. Long-term effect of intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Guoji Yanke Zazhi(Int Eye Sci) 2012;12(12) :2322-2325 摘要 目的:探讨玻璃体腔注射贝伐单抗(IVB) 治疗慢性中心性 浆液性脉络膜视网膜病变(central serous chorioretinopathy, CSC) 的安全性和长期临床疗效。 方法:我们 给 予 6 例 6 眼 慢 性 CSC 患 者 玻 璃 体 腔 注 射 1郾 25mg / 0. 05mL IVB 治疗。 5 例患者在第一次注射后 3mo 接受了第二次相同剂量的注射。 注射后 1,3,6,12,24mo 时随访观察。 观察指标包括治疗前后的最佳矫正视力、眼 压、OCT、眼底荧光素造影(FFA) 。 结果:第一次玻璃体腔注射 IVB 后,2 例患者视网膜下液
fatcat:q3shfvhfh5d5rcu3obvu5snu7a